Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Interview with Founder Tom Bailey: Blister Dose Delivery Uniformity (DDU)

Georgia Lewis: 18 May 2026

Dose Delivery Uniformity (DDU) is one of the most persistent challenges in dry-powder inhaler development, and few have tackled it more directly...

Read More
How our robotic isolator technology is setting a new standard for aseptic fill-finish

How our robotic isolator technology is setting a new standard for aseptic fill-finish

David Johnson: 15 April 2026

In the world of pharmaceutical manufacturing, our robotic isolator technology sets a new standard for aseptic fill-finish technology. By integrating...

Read More
Key Factors to Consider During the Design Process in Aseptic Manufacturing

Key Factors to Consider During the Design Process in Aseptic Manufacturing

David Johnson: 13 April 2026

Demand for the design and development of specialist aseptic manufacturing solutions is being driven by the significant growth in biological drug...

Read More